{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:13:31Z","timestamp":1755224011147,"version":"3.43.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ccl.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T13:18:15Z","timestamp":1728393495000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies"],"prefix":"10.1016","volume":"43","author":[{"given":"Hoda","family":"Sayegh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Zagouras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Waliany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.ccl.2024.08.006_bib1","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2024.08.006_bib2","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A\u00a0population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.ccl.2024.08.006_bib3","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ccl.2024.08.006_bib4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.clml.2015.07.638","article-title":"Trends and disparities in cardiovascular mortality among survivors of Hodgkin lymphoma","volume":"15","author":"Al-Kindi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.ccl.2024.08.006_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cam4.4862","article-title":"Hypertensive events after the initiation of contemporary cancer therapies for breast cancer control","volume":"12","author":"Carter","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.ccl.2024.08.006_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ccl.2024.08.006_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.ccl.2024.08.006_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaccao.2019.08.012","article-title":"Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor","volume":"1","author":"Waliany","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ccl.2024.08.006_bib9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/HYPERTENSIONAHA.117.09275","article-title":"Hypertension and VEGF (vascular endothelial growth factor) receptor tyrosine kinase inhibition: effects on renal function","volume":"70","author":"Boursiquot","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ccl.2024.08.006_bib10","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1073\/pnas.1301331110","article-title":"Anti-VEGF\u2013 and anti-VEGF receptor\u2013induced vascular alteration in mouse healthy tissues","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ccl.2024.08.006_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ccl.2024.08.006_bib12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ccl.2024.08.006_bib13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ccl.2024.08.006_bib14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ccl.2024.08.006_bib15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2015.368","article-title":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients","volume":"113","author":"Donskov","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ccl.2024.08.006_bib16","doi-asserted-by":"crossref","first-page":"e028050","DOI":"10.1161\/JAHA.122.028050","article-title":"Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study","volume":"12","author":"van Dorst","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ccl.2024.08.006_bib17","doi-asserted-by":"crossref","first-page":"30644","DOI":"10.1074\/jbc.274.43.30644","article-title":"Syk and Bruton\u2019s tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt","volume":"274","author":"Craxton","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ccl.2024.08.006_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"25","key":"10.1016\/j.ccl.2024.08.006_bib19","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"NEJM"},{"issue":"22","key":"10.1016\/j.ccl.2024.08.006_bib20","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ccl.2024.08.006_bib21","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ccl.2024.08.006_bib22","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ccl.2024.08.006_bib23","doi-asserted-by":"crossref","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ccl.2024.08.006_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ccl.2024.08.006_bib25","doi-asserted-by":"crossref","first-page":"e1057385","DOI":"10.1080\/2162402X.2015.1057385","article-title":"Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ccl.2024.08.006_bib26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.ccl.2024.08.006_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/01.RES.0000031956.29928.62","article-title":"Phosphatidylinositol 3-kinase","volume":"91","author":"Sata","year":"2002","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.ccl.2024.08.006_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"10245","key":"10.1016\/j.ccl.2024.08.006_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ccl.2024.08.006_bib30","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.ccl.2024.08.006_bib31","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2024.08.006_bib32","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"TOUR- MALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccl.2024.08.006_bib33","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1016\/j.clml.2020.04.014","article-title":"Drug-induced thrombotic microangiopathy with concurrent proteasome inhibitor use in the treatment of multiple myeloma: a case series and review of the literature","volume":"20","author":"Monteith","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.ccl.2024.08.006_bib34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1096\/fj.03-0054com","article-title":"Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway","volume":"18","author":"Stangl","year":"2004","journal-title":"Faseb J"},{"key":"10.1016\/j.ccl.2024.08.006_bib35","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","article-title":"Regulation of proteasome assembly and activity in health and disease","volume":"19","author":"Rousseau","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.ccl.2024.08.006_bib36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.ccl.2024.08.006_bib37","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ccl.2024.08.006_bib38","unstructured":"U.S. Food and Drug Administration (FDA). Tafinlar (dabrafenib) [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib39","unstructured":"U.S. Food and Drug Administration (FDA). Mekinist (trametinib) [package insert]. 2024."},{"issue":"8","key":"10.1016\/j.ccl.2024.08.006_bib40","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ccl.2024.08.006_bib41","first-page":"628","article-title":"Cardiotoxicity of BRAF\/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores","volume":"5","author":"Glen","year":"2023","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"12","key":"10.1016\/j.ccl.2024.08.006_bib42","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.jtho.2021.07.030","article-title":"Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC","volume":"16","author":"Waliany","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6892","key":"10.1016\/j.ccl.2024.08.006_bib43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ccl.2024.08.006_bib44","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1056\/NEJMcibr1013704","article-title":"Resistance to BRAF inhibition in melanomas","volume":"364","author":"Solit","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2024.08.006_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"issue":"20","key":"10.1016\/j.ccl.2024.08.006_bib46","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2024.08.006_bib47","doi-asserted-by":"crossref","first-page":"23065","DOI":"10.1074\/jbc.M200328200","article-title":"c-Raf\/MEK\/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells","volume":"277","author":"Iijima","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"41","key":"10.1016\/j.ccl.2024.08.006_bib48","doi-asserted-by":"crossref","first-page":"69477","DOI":"10.18632\/oncotarget.17704","article-title":"BRAF\/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.ccl.2024.08.006_bib49","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"10.1016\/j.ccl.2024.08.006_bib50","doi-asserted-by":"crossref","first-page":"26069","DOI":"10.1074\/jbc.M605040200","article-title":"CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1","volume":"281","author":"Isenberg","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ccl.2024.08.006_bib51","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1056\/NEJMsa0910784","article-title":"Reimbursement policy and androgen-deprivation therapy for prostate cancer","volume":"363","author":"Shahinian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2024.08.006_bib52","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","article-title":"Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses","volume":"40","author":"Hu","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"27","key":"10.1016\/j.ccl.2024.08.006_bib53","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ccl.2024.08.006_bib54","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00345-014-1439-6","article-title":"Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis","volume":"33","author":"Carneiro","year":"2015","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.ccl.2024.08.006_bib55","doi-asserted-by":"crossref","first-page":"e000082","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American heart association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circulation Genomic and Precision Medicine"},{"issue":"5","key":"10.1016\/j.ccl.2024.08.006_bib56","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1016\/j.clgc.2019.07.001","article-title":"New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes","volume":"17","author":"Di Nunno","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ccl.2024.08.006_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40885-019-0116-x","article-title":"Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis","volume":"25","author":"Zhu","year":"2019","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.ccl.2024.08.006_bib58","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of cyp17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2024.08.006_bib59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of cyp17a1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ccl.2024.08.006_bib60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41467-019-08290-2","article-title":"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs","volume":"10","author":"Yimit","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ccl.2024.08.006_bib61","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1200\/JCO.2005.01.4092","article-title":"Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2024.08.006_bib62","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2024.08.006_bib63","first-page":"247","article-title":"Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in\u00a0vitro","volume":"23","author":"Nuver","year":"2010","journal-title":"Oncol Rep"},{"issue":"11","key":"10.1016\/j.ccl.2024.08.006_bib64","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/annonc\/mdv369","article-title":"Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors","volume":"26","author":"Boer","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ccl.2024.08.006_bib65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-8-7","article-title":"Long-term platinum retention after treatment with cisplatin and oxaliplatin","volume":"8","author":"Brouwers","year":"2008","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.ccl.2024.08.006_bib66","unstructured":"U.S. Food and Drug Administration (FDA). Retevmo (selpercatinib) [package insert]. 2022."},{"key":"10.1016\/j.ccl.2024.08.006_bib67","unstructured":"U.S. Food and Drug Administration (FDA). Gavreto (pralsetinib) [package insert]. 2023."},{"issue":"10","key":"10.1016\/j.ccl.2024.08.006_bib68","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ccl.2024.08.006_bib69","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ccl.2024.08.006_bib70","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.ccl.2024.08.006_bib71","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2014.36","article-title":"RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis","volume":"110","author":"Tsuta","year":"2014","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ccl.2024.08.006_bib72","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.ccl.2024.08.006_bib73","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00467-011-1928-4","article-title":"Glucocorticoid-induced hypertension","volume":"27","author":"Goodwin","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"10.1016\/j.ccl.2024.08.006_bib74","first-page":"2208","article-title":"Early arterial intimal thickening and plaque is related with treatment regime and cardiovascular disease risk factors in young adults following childhood hematopoietic stem cell transplantation","volume":"9","author":"Sundholm","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"10.1016\/j.ccl.2024.08.006_bib75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bbmt.2009.11.018","article-title":"Hypertension in long-term survivors of pediatric hematopoietic cell transplantation","volume":"16","author":"Hoffmeister","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement_1","key":"10.1016\/j.ccl.2024.08.006_bib76","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1182\/blood-2019-129321","article-title":"Prevalence and associated factors for arterial hypertension in adults following hematopoietic stem cell transplantation","volume":"134","author":"Chalela","year":"2019","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.ccl.2024.08.006_bib77","first-page":"269","article-title":"Pathogenesis of calcineurin inhibitor-induced hypertension","volume":"25","author":"Hoorn","year":"2012","journal-title":"J\u00a0Nephrol"},{"issue":"6","key":"10.1016\/j.ccl.2024.08.006_bib78","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ccl.2024.08.006_bib79","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"41","key":"10.1016\/j.ccl.2024.08.006_bib80","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ccl.2024.08.006_bib81","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ccl.2024.08.006_bib82","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"Mir","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ccl.2024.08.006_bib83","unstructured":"U.S. Food and Drug Administration (FDA). Sunitinib malate (sunitinib malate) [package insert]. 2021."},{"key":"10.1016\/j.ccl.2024.08.006_bib84","unstructured":"U.S. Food and Drug Administration (FDA). Sorafenib [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib85","unstructured":"U.S. Food and Drug Administration (FDA). Pazopanib [package insert]. 2024."},{"key":"10.1016\/j.ccl.2024.08.006_bib86","unstructured":"U.S. Food and Drug Administration (FDA). Inlyta (axitinib) [package insert]. 2022."},{"key":"10.1016\/j.ccl.2024.08.006_bib87","unstructured":"U.S. Food and Drug Administration (FDA). Cabometyx (cabozantinib) [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib88","unstructured":"U.S. Food and Drug Administration (FDA). Avastin (bevacizumab) [package insert]. 2022."},{"key":"10.1016\/j.ccl.2024.08.006_bib89","unstructured":"U.S. Food and Drug Administration (FDA). Cyramza (ramucirumab) [package insert]. 2022."},{"key":"10.1016\/j.ccl.2024.08.006_bib90","unstructured":"U.S. Food and Drug Administration (FDA). Imbruvica (ibrutinib) [package insert]. 2024."},{"key":"10.1016\/j.ccl.2024.08.006_bib91","unstructured":"U.S. Food and Drug Administration (FDA). Calquence (acalabrutinib) [package insert]. 2022."},{"key":"10.1016\/j.ccl.2024.08.006_bib92","unstructured":"U.S. Food and Drug Administration (FDA). Brukinsa (zanubrutinib) [package insert]. 2024."},{"key":"10.1016\/j.ccl.2024.08.006_bib93","unstructured":"U.S. Food and Drug Administration (FDA). Bortezomib [package insert]. 2022."},{"key":"10.1016\/j.ccl.2024.08.006_bib94","unstructured":"U.S. Food and Drug Administration (FDA). Ninlaro (ixazomib) [package insert]. 2024."},{"key":"10.1016\/j.ccl.2024.08.006_bib95","unstructured":"U.S. Food and Drug Administration (FDA). Kyprolis (carfilzomib) [package insert]. 2022."},{"key":"10.1016\/j.ccl.2024.08.006_bib96","unstructured":"U.S. Food and Drug Administration (FDA). Zelboraf (vemurafenib) [package insert]. 2020."},{"key":"10.1016\/j.ccl.2024.08.006_bib97","unstructured":"U.S. Food and Drug Administration (FDA). Cotellic (cobimetinib) [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib98","unstructured":"U.S. Food and Drug Administration (FDA). Braftovi (encorafenib) [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib99","unstructured":"U.S. Food and Drug Administration (FDA). Mektovi (binimetinib) [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib100","unstructured":"U.S. Food and Drug Administration (FDA). Leuprolide acetate [package insert]. 2024."},{"key":"10.1016\/j.ccl.2024.08.006_bib101","unstructured":"U.S. Food and Drug Administration (FDA). Firmagon (degarelix) [package insert]. 2020."},{"key":"10.1016\/j.ccl.2024.08.006_bib102","unstructured":"U.S. Food and Drug Administration (FDA). Orgovyx (relugolix) [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib103","unstructured":"U.S. Food and Drug Administration (FDA). Bicalutamide [package insert]. 2022."},{"key":"10.1016\/j.ccl.2024.08.006_bib104","unstructured":"U.S. Food and Drug Administration (FDA). Xtandi (enzalutamide) [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib105","unstructured":"U.S. Food and Drug Administration (FDA). Erleada (apalutamide) [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib106","unstructured":"U.S. Food and Drug Administration (FDA). Nubeqa (darolutamide) [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib107","unstructured":"U.S. Food and Drug Administration (FDA). Abiraterone acetate [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib108","unstructured":"U.S. Food and Drug Administration (FDA). Cisplatin [package insert]. 2023."},{"key":"10.1016\/j.ccl.2024.08.006_bib109","unstructured":"U.S. Food and Drug Administration (FDA). Carboplatin [package insert]. 2022."},{"key":"10.1016\/j.ccl.2024.08.006_bib110","unstructured":"U.S. Food and Drug Administration (FDA). Oxaliplatin [package insert]. 2023."}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865124000869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865124000869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T10:35:31Z","timestamp":1754994931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865124000869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0733865124000869"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2024.08.006","relation":{},"ISSN":["0733-8651"],"issn-type":[{"type":"print","value":"0733-8651"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}